650 Gateway Boulevard,
South San Francisco
About DNA Script
DNA Script is a leading company in manufacturing de novo synthetic nucleic acids using a proprietary enzymatic technology. DNA Script's approach leverages nature's billions of years of evolution in synthesizing DNA to set a new standard for how nucleic acids are made and accelerate the adoption of synthetic biology across diverse disciplines such as biopharma, sustainable chemistry and data storage. DNA Script’s first product will be a DNA printer. On course to hit the shelves in 2021, this benchtop instrument will enable researchers to target and program specific areas of the genome.
To date, DNA Script has raised over $100M of financing, mostly through leading investors such Casdin, Agilent, Danaher, LSP, Bpifrance, Illumina Ventures, Merck Ventures, Sofinnova Partners, Kurma Partners, Idinvest.
DNA Script has its research facility headquartered in Paris, France, and is in the process of expanding its commercial and development teams in South San Francisco.
We’re science-driven thinkers, makers, dreamers and do-ers. Our goal is to develop technology to accelerate advances in life sciences and health.
DNA Script is now moving to a new stage of development, i.e. commercialization. That’s why we are looking for new talents in different fields: R&D, manufacturing and supply chain, sales and marketing, industrial and IT engineering, etc.
If you are passionate about life sciences and their projects, curious, motivated, proactive and want to invest in a company with an innovative project, do not hesitate to send us your application!
Join DNA Script means :
- Participate and bring to life a project that makes sense and will have a real impact on future generations
- Be part of a strong scientific and technical environment: a technology that pushes the limits of what is today possible in the world of DNA synthesis. Collaborations with MIT, Harvard etc.
- A scalable position: you will benefit from training, work on transversal projects, etc.
- Discover different cultures because at DNA Script we come from all over the world.
- Friday breakfast, afterworks and teambuildings frequently
- A management with values Excellence, transparency and kindness, where the well-being is not just a promise!
French office: 67 avenue de Fontainebleau, 94 270 Le Kremlin-Bicêtre
Discover Dna Script with Sylvain, COO & cofounder
29 articles with DNA Script
Life sciences and biopharma companies strengthen their leadership teams and boards with these Movers & Shakers.
DNA Script, a world leader in Enzymatic DNA Synthesis for DNA on demand, has added life sciences veteran Chris Barbazette as Chief Commercial Officer to its leadership team.
DNA Script Launches Early Access Program for Latest Advancements to the SYNTAX Platform and Enzymatic DNA Synthesis Technology
DNA Script, a world leader in Enzymatic DNA Synthesis for DNA on demand, announced the launch of a new program for customers of their SYNTAX System, in which organizations receive early access to the latest advancements of their EDS technology.
DNA Script Partners with Asia-Pacific Distributors as Part of Global Expansion to Meet Demand for Same-day Enzymatic DNA Synthesis
DNA Script has reached agreements with several leading biotechnology distribution companies throughout the Asia-Pacific region, including Cold Spring Biotech Corp., Research Instruments Pte. Ltd., Premas Life Sciences Pvt. Ltd. and Bio-Medical Science Co. Ltd.
DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) and DNA on demand, has been named to Fast Company ’s prestigious annual list of the World’s Most Innovative Companies for 2022.
DNA Script, a leader in Enzymatic DNA Synthesis and DNA on demand, has inked a multi-million dollar, multi-year contract with Wellcome Leap to accelerate RNA products, including mRNA vaccines, and advance RNA therapies.
Company to Present Monday, January 10, 2022, at 2 p.m. EST.
Here's who rang in the New Year by joining the NASDAQ or raising private equity funds.
DNA Script, a pioneer in Enzymatic DNA Synthesis for on-demand DNA printing, announced the completion of its Series C financing, raising $200 million of new capital.
DNA Script announced it secured a $200 million Series C financing, bringing the total amount raised by the biotech company to $315 million since its founding in 2014.
DNA Script, a leader in Enzymatic DNA Synthesis, announced the CE marking of its SYNTAX System, the first EDS-powered benchtop DNA printer.
DNA Script, a leader in Enzymatic DNA Synthesis, announced that Blanche Savary de Beauregard has joined the company as General Counsel.
DNA Script to Develop Next Generation of Enzymatic DNA Synthesis Printers with $2.2 Million Grant Award from the National Human Genome Research Institute of the NIH
DNA Script, a leader in benchtop enzymatic DNA synthesis, announced that the company has received a $2.2 million grant award from the National Human Genome Research Institute of the National Institutes of Health to support the ongoing development of next generation printers to enzymatically print synthetic DNA and RNA as a follow-on to their recently launched SYNTAX System.
10/27/2021While the volatility of the market has some shying away from going public, private investment dollars are still rolling in each week. Check out our top picks.
DNA Script Raises $165M in Oversubscribed Series C Financing to Accelerate Commercialization of Enzymatic DNA Printing Platform
DNA Script, a pioneer in Enzymatic DNA Synthesis and DNA printing on demand, announced it has raised $165 million in a Series C financing led by Coatue Management and Catalio Capital Management, whose representatives have joined as Board observers.
DNA Script Appoints Don Kania as Chairman of the Board of Directors, Catherine Moukheibir as Audit Chair and Bonnie Anderson as Independent Director
DNA Script, a leader in Enzymatic DNA Synthesis, announced the appointment of Don Kania, Ph.D. as Chairman of the Board of Directors, Catherine Moukheibir as Audit Chair and Bonnie Anderson as independent new members of the Board.
DNA Script Advances Evaluation Program for the SYNTAX System, the First Benchtop DNA Printer Powered By Enzymatic Synthesis
DNA Script, a leading pioneer in enabling enzymatic DNA synthesis on demand, announced the third and final phase of its evaluation program for the SYNTAX System, the world's first benchtop printer powered by Enzymatic DNA Synthesis technology.
Company will receive up to $5 Million in grant funds from DARPA as part of the agency's Nucleic Acids On-Demand World-Wide Program to plan for and prevent the next viral pandemic
GE Research selected DNA Script to join a collaboration working on a rapid response, mobile platform to develop on-demand production of nucleic acid-based vaccines and therapies related to biological threats.
DNA Script Signs Innovation Development Contract With French Defence Innovation Agency to Enable On-Demand Diagnostics Against Emerging Biothreats
Company will receive $1.6 Million to develop a qPCR probe manufacturing platform to enable the fast detection of highly pathogenic viruses and bacteria